HALEOSLABS (HALEOSLABS) Fair Value & Analysis

Healthcare · Market cap ₹4.9B

H HALEOSLABS HALEOSLABS · NSE

Price₹1,631

Fair Value₹885.03

Upside-45.7%

Quality55/100

Watch HALEOSLABS for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range ₹619.52 – ₹1,151

Fair value as of: Jul 3, 2026

From 14 valuation models · updated today

Share price +13.0% over the past month.

Price vs Fair Value (12 months)

12‑month range ₹1,077 – ₹1,690 · fair‑value band ₹619.52 – ₹1,151 · the ₹1,631 price screens above the ₹885.03 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

HALEOSLABS (HALEOSLABS) currently trades at ₹1,631, while our model-based Fair Value estimate is ₹885.03 — implying the stock looks roughly 45.7% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, HALEOSLABS generated revenue of ₹3.3B at a net margin of 5.2%. Revenue declined 15.7% year over year. It earns a return on equity of 8.1%. Net debt stands at ₹1.1B. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹3.3B

Revenue growth (YoY) -15.7%

Net margin 5.2%

Return on equity 8.1%

Free cash flow −₹229M FY2026

P/E ratio 28.5

More key figures

Operating margin 0.4%

EPS (TTM) ₹57.32

Dividend yield 0.1%

EPS growth (YoY) -85.4%

Net debt ₹1.1B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

HALEOSLABS reported revenue of ₹3.3B in FY2026 versus ₹3.5B in FY2022, a compound −1.0%/yr. Reported net income was ₹173M in FY2026, compounding −9.1%/yr from FY2022.

Revenue −1.0%/yr

FY22 ₹3.5B

FY23 ₹3.1B

FY24 ₹3.0B

FY25 ₹3.4B

FY26 ₹3.3B

Net income −9.1%/yr

FY22 ₹253M

FY23 ₹115M

FY24 ₹90.9M

FY25 ₹201M

FY26 ₹173M

Is HALEOSLABS fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	5,617 MXN	-27%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€247.60	€180.06	-27%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$286.41	$106.81	-63%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is HALEOSLABS (HALEOSLABS) undervalued?

As of Jul 3, 2026, our model estimates a fair value of ₹885.03 versus a price of ₹1,631 — about −46% (overvalued). Model-based estimate, not financial advice.

What is the fair value of HALEOSLABS?

Our model-based fair value for HALEOSLABS is ₹885.03 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹1,631.

What is the quality score of HALEOSLABS?

HALEOSLABS has a Quality Score of 55/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of HALEOSLABS (HALEOSLABS)?

HALEOSLABS reported trailing-twelve-month revenue of about ₹3.3B (latest available figure, as of Jul 3, 2026).

What is the net profit margin of HALEOSLABS?

The net profit margin of HALEOSLABS is about 5.2%, meaning it keeps roughly 5.2% of revenue as net income. Based on the latest reported figures.

Does HALEOSLABS pay a dividend?

HALEOSLABS currently shows a dividend yield of about 0.09% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.